Spruce Non Current Assets Total vs Total Current Liabilities Analysis
| SPRB Stock | USD 0.48 0.01 2.04% |
Spruce Biosciences financial indicator trend analysis is much more than just breaking down Spruce Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spruce Biosciences is a good investment. Please check the relationship between Spruce Biosciences Non Current Assets Total and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.
Non Current Assets Total vs Total Current Liabilities
Non Current Assets Total vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spruce Biosciences Non Current Assets Total account and Total Current Liabilities. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Spruce Biosciences' Non Current Assets Total and Total Current Liabilities is 0.13. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Spruce Biosciences, assuming nothing else is changed. The correlation between historical values of Spruce Biosciences' Non Current Assets Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Spruce Biosciences are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Assets Total i.e., Spruce Biosciences' Non Current Assets Total and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.13 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Spruce Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Spruce Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Spruce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spruce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 62.6 M, whereas Selling General Administrative is forecasted to decline to about 8.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 68K | 74K | 78K | 49.3K | Total Operating Expenses | 42.1M | 47.3M | 62.1M | 37.4M |
Spruce Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Spruce Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spruce Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.7M | 162.9M | 126.5M | 85.6M | 103.9M | 89.5M | |
| Other Current Liab | 1.2M | 3.3M | 5.7M | 9.3M | 14.3M | 15.1M | |
| Total Current Liabilities | 4.3M | 9.8M | 8.9M | 12.4M | 24.5M | 25.7M | |
| Total Stockholder Equity | (30.6M) | 149.4M | 111.4M | 68.5M | 76.5M | 65.5M | |
| Net Tangible Assets | (30.6M) | 149.4M | 111.4M | 68.5M | 78.8M | 61.8M | |
| Net Debt | 521K | (151.0M) | (36.6M) | (18.3M) | (91.7M) | (87.1M) | |
| Retained Earnings | (31.3M) | (60.8M) | (103.1M) | (149.3M) | (197.2M) | (187.4M) | |
| Accounts Payable | 1.9M | 3.6M | 2.8M | 1.4M | 3.3M | 2.8M | |
| Cash | 3.9M | 157.2M | 42.7M | 24.5M | 96.3M | 60.3M | |
| Non Current Assets Total | 40K | 2.5M | 34.6M | 2.0M | 1.8M | 1.7M | |
| Non Currrent Assets Other | 40K | 477K | 653K | 55.2M | 582K | 552.9K | |
| Other Assets | 40K | 2.5K | 513K | 640K | 1.0 | 0.95 | |
| Cash And Short Term Investments | 3.9M | 157.2M | 89.0M | 79.1M | 96.3M | 78.8M | |
| Common Stock Shares Outstanding | 22.3M | 23.3M | 23.4M | 23.5M | 38.5M | 24.9M | |
| Liabilities And Stockholders Equity | 4.7M | 162.9M | 126.5M | 85.6M | 103.9M | 89.5M | |
| Non Current Liabilities Total | 31.0M | 3.7M | 6.2M | 4.7M | 3.0M | 2.8M | |
| Other Current Assets | 513K | 3.2M | 2.9M | 4.5M | 5.8M | 3.2M | |
| Other Stockholder Equity | 664K | 373.1M | 214.7M | 218.4M | 273.7M | 198.2M | |
| Total Liab | 35.3M | 13.5M | 15.1M | 17.2M | 27.4M | 17.5M | |
| Net Invested Capital | (26.2M) | 153.9M | 116.2M | 73.4M | 79.8M | 69.6M | |
| Total Current Assets | 4.7M | 160.4M | 91.9M | 83.6M | 102.2M | 82.0M | |
| Net Working Capital | 349K | 150.6M | 83.0M | 71.2M | 77.7M | 70.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.